TerminatedPhase 2NCT01824303
Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis
Studying Interstitial cystitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Allergan
- Principal Investigator
- Curtis Nickel, MD, MSN NPQueen's University/Kingston General Hospital/Ontario Canada
- Intervention
- LiRIS 400 mg(drug)
- Enrollment
- 31 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2013 – 2014
Study locations (17)
- Citrus Valley Medical Research , Inc., Glendora, California, United States
- Atlantic Urological Associates, Daytona Beach, Florida, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
- The UrogynecologyCenter, LLC, Overland Park, Kansas, United States
- Female Pelvic Medicine & Urogynecology Institute of MI, Grand Rapids, Michigan, United States
- William Beaumont Hospitals, Royal Oak, Michigan, United States
- North Shore - Long Island Jewish Heath System - Monter Cancer Center, New Hyde Park, New York, United States
- Premier Medical Group of the Hudson Valley PC, Newburgh, New York, United States
- Premier Medical Group of the Hudson Valley PC, Poughkeepsie, New York, United States
- Alliance Urology Specialists, PA, Greensboro, North Carolina, United States
- Wake Forest Baptist Health, Winston-Salem, North Carolina, United States
- MetroHealth Medical Center, Cleveland, Ohio, United States
- Medical University of South Carolina, Charleston, South Carolina, United States
- Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States
- Volunteer Research Group, University of Tennessee Medical Center, Knoxville, Tennessee, United States
- +2 more locations on ClinicalTrials.gov
Collaborators
TARIS Biomedical, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01824303 on ClinicalTrials.govOther trials for Interstitial cystitis
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT06752603A Clinical Study of ONO-1110 in Patients With Hunner Type Interstitial CystitisOno Pharmaceutical Co. Ltd
- RECRUITINGEARLY PHASE1NCT04734106Safety and Efficacy of Aloe Vera in the Management of the Symptoms of Interstitial CystitisWake Forest University Health Sciences
- RECRUITINGNANCT06366269Acupuncture First for IC/BPSUniversity Hospitals Cleveland Medical Center
- RECRUITINGPHASE2NCT06394830Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)Vaneltix Pharma, Inc.
- RECRUITINGNCT06729151Effect of Intradetrusor onabotulinumtoxinA Injection Versus Conservative Management on Female Sexual Function in Patients With Bladder Pain SyndromeWalter Reed National Military Medical Center
- RECRUITINGNCT06719232Evaluating the Efficacy and Patient Experience of Catheter-Free Intravesical InstillationJahn Ferenc South Pest Teaching Hospital
- RECRUITINGPHASE2, PHASE3NCT06096597Amniotic Membrane Therapy for Interstitial Cystitis/Painful Bladder SyndromeDavid Sheyn
- RECRUITINGNANCT06299683Pain Type and Interstitial Cystitis/Bladder Pain Syndrome TreatmentVanderbilt University Medical Center